AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
Amgen will host a webcast call for investors at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on Dec. 5, 2022, at 8:00 a.m. ET. David M. Reese, M.D., will present Phase 1 data on AMG 133, a novel bispecific receptor targeting GIPR and GLP-1. The webcast will be publicly accessible and archived for 90 days post-event.
Amgen, a leader in innovative human therapeutics, aims to address high unmet medical needs and has a robust pipeline. For more details, visit www.amgen.com.
- None.
- None.
THOUSAND OAKS, Calif., Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.
The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.
For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.
CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media)
Arvind Sood, 805-447-1060 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-wcirdc-2022-301688142.html
SOURCE Amgen
FAQ
What is the purpose of Amgen's webcast on December 5, 2022?
Who will present at the Amgen webcast?
How can I access Amgen's webcast on December 5, 2022?
What is AMG 133 that Amgen is discussing in the webcast?
What event is Amgen's webcast associated with?
